Dare Bioscience, Inc. quarterly report, Q2 FY2020

Dare Bioscience, Inc. — Q2 2020 Form 10-Q

Reporting period: Three and six months ended June 30, 2020. Dare is a clinical-stage women’s health biopharmaceutical company with no approved or commercialized products and no product revenue. Its portfolio includes candidates in contraception, fertility, and sexual and vaginal health.

Financial results and liquidity

MetricQ2 2020Q2 2019Six months 2020Six months 2019
Revenue$0$0$0$0
Operating expenses$7.13 million$3.98 million$11.38 million$7.07 million
Net loss$7.12 million$3.95 million$11.38 million$7.00 million
Net loss per share, basic and diluted$0.27$0.29$0.45$0.57
Cash used in operating activitiesNot separately reported for the quarter$10.68 million$6.33 million
  • Second-quarter R&D expense rose to $5.55 million from $2.51 million; the company attributed the increase primarily to DARE-BV1 and Ovaprene development, DARE-LARC1 preclinical work, and personnel costs. For the first half, R&D expense increased to $7.93 million from $4.21 million.
  • At June 30, cash and cash equivalents were $5.35 million, total assets $8.57 million, and total liabilities $8.26 million. Working capital was approximately $1.7 million. Stockholders’ equity was $311,255.
  • The company reported a $367,285 Paycheck Protection Program loan, due April 2022, at 1% interest. It intends to seek full forgiveness, but forgiveness is not assured. Current liabilities also included $416,945 of current lease liabilities; long-term lease liabilities were $175,270.
  • Financing activities provided $11.28 million in the first half, chiefly from equity sales and warrant exercises, plus the PPP loan. Cash increased by $566,765 over the period.

Material changes versus prior period

  • First-half net loss increased by $4.37 million year over year, while operating cash use increased by $4.36 million. Operating expenses rose $4.31 million, driven mainly by higher R&D and general and administrative costs.
  • Common shares outstanding increased from 19.68 million at December 31, 2019 to 28.52 million at June 30, 2020, reflecting equity issuance and warrant exercises. By August 11, 2020, 31.55 million shares were outstanding.
  • Cash rose from $4.78 million at year-end 2019 to $5.35 million, but the company continued to incur substantial operating losses and cash burn.

Outlook, developments, and risks

  • Going concern: Management stated that available cash was insufficient to meet working-capital and other liquidity needs for at least the next 12 months from the financial statements’ issuance. The filing says this raises substantial doubt about the company’s ability to continue as a going concern. Additional capital is needed; without it, programs could be delayed, reduced, or discontinued, or operations could cease.
  • Development plans: Dare commenced a Phase 3 DARE-BV1 study in June 2020, targeting approximately 240 participants at about 40 U.S. sites. It anticipated topline results by year-end 2020 and, if successful, an NDA filing in early 2021; estimated program costs through filing were approximately $10 million. The pivotal Ovaprene study was being designed for about 250 women, with topline data targeted by year-end 2022. COVID-19-related disruption led the company to reassess the start timing of the Sildenafil Cream Phase 2b trial, while it continued to target topline results by year-end 2021. DARE-HRT1’s Phase 1 study began in Australia in July 2020, with topline data anticipated in the first half of 2021 and estimated study costs of approximately $2.5 million. These are management expectations, not guaranteed outcomes.
  • Bayer/Ovaprene agreement: Bayer paid a $1 million upfront fee, recorded as deferred revenue at June 30. Bayer may, at its sole discretion, pay an additional $20 million to activate its U.S. license after reviewing pivotal-trial results. Potential milestone payments total up to $310 million, plus tiered royalties and a share of sublicense revenue. Bayer may terminate on 90 days’ notice.
  • Capital raised after quarter-end: Through August 11, Dare reported net proceeds of approximately $2.3 million from ATM sales and $1.1 million from Lincoln Park equity sales, plus approximately $121,000 from warrant exercises. These equity issuances add to potential shareholder dilution.
  • COVID-19: The company cited possible delays and added costs from clinical-site and patient-enrollment disruption, supply-chain interruptions, third-party constraints, regulatory delays, and reduced access to capital. It said the full effects were uncertain.
  • Other items: The NIH awarded approximately $731,000 in final grant funding for Ovaprene development, subject to eligible expenses and reimbursement. A further approximately $1.9 million of Gates Foundation funding received for DARE-LARC1 remained deferred pending eligible R&D spending. Management reported effective disclosure controls as of June 30; no material pending legal proceedings were disclosed.

Important facts for investors to verify

  • Current cash runway, operating burn, and the timing and terms of additional financing; confirm whether management’s liquidity needs have changed since the filing.
  • Enrollment progress, trial timelines, costs, and results for DARE-BV1, Ovaprene, Sildenafil Cream, and DARE-HRT1, including any COVID-19-related changes.
  • Whether Bayer elects to pay the additional $20 million and activate the Ovaprene license, and the implications of its termination rights.
  • Further share issuance under the ATM and Lincoln Park agreements, remaining capacity and restrictions, and resulting dilution.
  • Whether the PPP loan is forgiven and whether grant reimbursements are received as expected.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.